Chaim Hurvitz - 21 Oct 2022 Form 4/A - Amendment Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Director
Signature
/s/ Chaim Hurvitz
Issuer symbol
NRXP
Transactions as of
21 Oct 2022
Net transactions value
+$514,905
Form type
4/A - Amendment
Filing time
23 Nov 2022, 15:09:34 UTC
Date Of Original Report
21 Nov 2022
Previous filing
10 Jun 2021
Next filing
27 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRXP Common Stock Purchase $284,934 +287,812 $0.9900 287,812 16 Nov 2022 Direct F1
transaction NRXP Common Stock Purchase $185,522 +171,780 +60% $1.08 459,592 17 Nov 2022 Direct F2
transaction NRXP Common Stock Purchase $44,449 +40,408 +8.8% $1.10 500,000 18 Nov 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
F2 The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
F3 The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10.